Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New PhaseBusiness Wire • 09/23/24
Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMOBusiness Wire • 09/16/24
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall SurvivalBusiness Wire • 09/14/24
Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall SurvivalBusiness Wire • 09/09/24
Natera to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceBusiness Wire • 08/28/24
Compared to Estimates, Natera (NTRA) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 08/09/24
Newell Brands' Sharpie and Paper Mate Pledge $1 Million to Boys & Girls Clubs of America to Inspire Creativity and Empower Youth NationwideBusiness Wire • 08/06/24
Enclara Pharmacia Announces Real-Time, Two-Way Medication Integration With MatrixCare's Electronic Health Record PlatformBusiness Wire • 08/06/24
New MultiCenter Prospective Study Demonstrates Signatera's Clinical Utility in Merkel Cell CarcinomaBusiness Wire • 07/26/24
Natera (NTRA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 07/25/24
Natera to Present at the 28th International Conference on Prenatal Diagnosis and TherapyBusiness Wire • 07/03/24
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal CancerBusiness Wire • 06/27/24
Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant PatientsBusiness Wire • 06/17/24
Natera to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceBusiness Wire • 06/03/24
Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024Business Wire • 05/30/24
Natera to Present at the 2024 Leerink Partners Healthcare Crossroads ConferenceBusiness Wire • 05/23/24
Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual MeetingBusiness Wire • 05/23/24
Why Natera Is 'A Stock To Focus On' Following Its Mighty Beat-And-RaiseInvestors Business Daily • 05/10/24